National Center for Advancing Translational Sciences; Notice of Meeting, 48191 [2022-16890]
Download as PDF
<![CDATA[
Federal Register / Vol. 87, No. 151 / Monday, August 8, 2022 / Notices
khammond on DSKJM1Z7X2PROD with NOTICES
submitted in response to this notice or
presented during the meeting. This
request for input is for planning
purposes only and is not a solicitation
for applications or an obligation on the
part of the U.S. Government to provide
support for any ideas identified in
response to the request. Please note that
the U.S. Government will not pay for
the preparation of any information
submitted or for its use of that
information.
Background Information on ICCVAM,
NICEATM, and SACATM
ICCVAM is an interagency committee
composed of representatives from 17
federal regulatory and research agencies
that require, use, generate, or
disseminate toxicological and safety
testing information. ICCVAM conducts
technical evaluations of new, revised,
and alternative safety testing methods
and integrated testing strategies with
regulatory applicability. ICCVAM also
promotes the scientific validation and
regulatory acceptance of testing
methods that more accurately assess the
safety and hazards of chemicals and
products and replace, reduce, or refine
animal use.
The ICCVAM Authorization Act of
2000 (42 U.S.C. 285l–3) establishes
ICCVAM as a permanent interagency
committee of NIEHS and provides the
authority for ICCVAM involvement in
activities relevant to the development of
alternative test methods. Additional
information about ICCVAM can be
found at https://ntp.niehs.nih.gov/go/
iccvam.
NICEATM administers ICCVAM,
provides scientific and operational
support for ICCVAM-related activities,
and conducts and publishes analyses
and evaluations of data from new,
revised, and alternative testing
approaches. NICEATM and ICCVAM
work collaboratively to evaluate new
and improved testing approaches
applicable to the needs of U.S. federal
agencies. NICEATM and ICCVAM
welcome the public nomination of new,
revised, and alternative test methods
and strategies for validation studies and
technical evaluations. Additional
information about NICEATM can be
found at https://ntp.niehs.nih.gov/go/
niceatm.
SACATM, established by the ICCVAM
Authorization Act [Section 285l–3(d)],
provides advice on priorities and
activities related to the development,
validation, scientific review, regulatory
acceptance, implementation, and
national and international
harmonization of new, revised, and
alternative toxicological test methods to
ICCVAM, NICEATM, and Director of
VerDate Sep<11>2014
21:34 Aug 05, 2022
Jkt 256001
NIEHS and NTP. Additional
information about SACATM, including
the charter, roster, and records of past
meetings, can be found at https://
ntp.niehs.nih.gov/go/167.
Dated: August 3, 2022.
Brian R. Berridge,
Associate Director, National Toxicology
Program.
[FR Doc. 2022–16954 Filed 8–5–22; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Center for Advancing
Translational Sciences; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Center for
Advancing Translational Sciences
Advisory Council.
This meeting is being held virtually
only; there is no in-person option. The
open sessions will be videocast and may
be accessed by the public from the NIH
Videocasting and Podcasting website
(https://videocast.nih.gov). Individuals
who need special assistance, such as
sign language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Center for
Advancing Translational Sciences Advisory
Council.
Date: September 22, 2022.
Closed: 11:00 a.m. to 12:00 p.m.
Agenda: To review, evaluate, and discuss
internal operations. To review and evaluate
grant applications.
Place: National Center for Advancing
Translational Sciences, National Institutes of
Health, One Democracy Plaza, Room 987/
989, 6701 Democracy Boulevard, Bethesda,
MD 20892 (Virtual Meeting).
Open: 1:00 p.m. to 6:00 p.m.
Agenda: Report from the Institute Director,
program updates, view and discuss Clearance
of Concepts.
Place: National Center for Advancing
Translational Sciences, National Institutes of
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
48191
Health, One Democracy Plaza, Room 987/
989, 6701 Democracy Boulevard, Bethesda,
MD 20892 (Virtual Meeting).
Contact Person: Anna L. Ramsey-Ewing,
Ph.D., Executive Secretary, National Center
for Advancing Translational Sciences, One
Democracy Plaza, Room 1072, Bethesda, MD
20892, 301–435–0809, anna.ramseyewing@
nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice no later than 15 days after the
meeting at NCATSCouncilInput@
mail.nih.gov. The statement should include
the name, address, telephone number and
when applicable, the business or professional
affiliation of the interested person.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.350, B—Cooperative
Agreements; 93.859, Biomedical Research
and Research Training, National Institutes of
Health, HHS)
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–16890 Filed 8–5–22; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
Periodically, the Substance Abuse and
Mental Health Services Administration
(SAMHSA) will publish a summary of
information collection requests under
the Office of Management and Budget
(OMB) review, in compliance with the
Paperwork Reduction Act (44 U.S.C.
chapter 35). To request a copy of these
documents, call the SAMHSA Reports
Clearance Officer on (240) 276–0361.
Proposed Project: Rural Emergency
Medical Services Training (EMS
Training) Monitoring
SAMHSA will monitor program
performance of its Rural Emergency
Medical Services Training (EMS
Training) grant program. The EMS
Training grantees will recruit and train
EMS personnel in rural areas with a
particular focus on addressing mental
and substance use disorders. To
accomplish this, the EMS Training
grantees conduct courses that qualify
graduates to serve in an EMS agency,
train EMS personnel as appropriate to
maintain licenses and certifications and
ensure EMS personnel are trained on
mental and substance use disorders and
E:\FR\FM\08AUN1.SGM
08AUN1
]]>Agencies
[Federal Register Volume 87, Number 151 (Monday, August 8, 2022)]
[Notices]
[Page 48191]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-16890]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Center for Advancing Translational Sciences; Notice of
Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of a meeting of the National Center for
Advancing Translational Sciences Advisory Council.
This meeting is being held virtually only; there is no in-person
option. The open sessions will be videocast and may be accessed by the
public from the NIH Videocasting and Podcasting website (https://videocast.nih.gov). Individuals who need special assistance, such as
sign language interpretation or other reasonable accommodations, should
notify the Contact Person listed below in advance of the meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Center for Advancing Translational
Sciences Advisory Council.
Date: September 22, 2022.
Closed: 11:00 a.m. to 12:00 p.m.
Agenda: To review, evaluate, and discuss internal operations. To
review and evaluate grant applications.
Place: National Center for Advancing Translational Sciences,
National Institutes of Health, One Democracy Plaza, Room 987/989,
6701 Democracy Boulevard, Bethesda, MD 20892 (Virtual Meeting).
Open: 1:00 p.m. to 6:00 p.m.
Agenda: Report from the Institute Director, program updates,
view and discuss Clearance of Concepts.
Place: National Center for Advancing Translational Sciences,
National Institutes of Health, One Democracy Plaza, Room 987/989,
6701 Democracy Boulevard, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Anna L. Ramsey-Ewing, Ph.D., Executive
Secretary, National Center for Advancing Translational Sciences, One
Democracy Plaza, Room 1072, Bethesda, MD 20892, 301-435-0809,
[email protected].
Any interested person may file written comments with the
committee by forwarding the statement to the Contact Person listed
on this notice no later than 15 days after the meeting at
[email protected]. The statement should include the
name, address, telephone number and when applicable, the business or
professional affiliation of the interested person.
(Catalogue of Federal Domestic Assistance Program Nos. 93.859,
Pharmacology, Physiology, and Biological Chemistry Research; 93.350,
B--Cooperative Agreements; 93.859, Biomedical Research and Research
Training, National Institutes of Health, HHS)
Miguelina Perez,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2022-16890 Filed 8-5-22; 8:45 am]
BILLING CODE 4140-01-P
